Curia is a global Contract Development and Manufacturing Organization with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing to make treatments broadly accessible to patients. We offer services across Small Molecules, Generic APIs, and Biologics backed by deep scientific expertise and a robust global network of resources and capabilities. Our dedicated teams, combined with advanced technologies, enable us to be both flexible and scalable, accelerating the delivery of your product to patients. From curiosity to cure, we are your trusted ally, delivering every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com | Curia is a global CDMO with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing. Our Biologics services span discovery to clinical manufacturing, including clinical and commercial fill-finish services, for antibodies, recombinant proteins, mRNA therapeutics and many large molecule products. Curia’s expertise and agility deliver a best-in-class experience across discovery, drug substance and drug product development and manufacturing. From curiosity to cure, we are your trusted ally to accelerate life-changing therapeutics. To learn more, visit us at https://curiaglobal.com/biologics/
Coriolis Pharma Research GmbH
Coriolis Pharma is a global contract research organization and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines. The company’s offerings include liquid and lyophilized freeze-dried drug formulation development from early stage to market approval and beyond, lyophilization freeze-drying process development, and analytical development under R&D and GMP. Non-GMP manufacturing services for a wide range of products complete the service offering. More than 725 clients – from start-ups to big pharma – already rely on Coriolis’s scientific expertise. For each project, our highly skilled scientists develop customized study designs that align with our customers’ drug development strategies. | Coriolis Pharma is a globally operating contract research and development organization (CRDO) and a leader in formulation research and development of biopharmaceutical drugs, including cell and gene therapy products and vaccines. We provide high-quality services for liquid and lyophilized drug products from early stage to commercialization and beyond. Manufacturing support and contract analytical services under R&D and GMP complete our service portfolio. Coriolis was founded in 2008 and currently employs more than 200 employees from over 36 nations around the world. | Coriolis Pharma is a globally operating, science‑driven contract research and development organization (CRDO) specializing in drug product development, formulation, lyophilization technologies, and advanced analytics for biopharmaceuticals. Founded in 2008 and with laboraties in Europe and the U.S., the company supports clients from early development to commercialization, offering both R&D and GMP-compliant analytical services across a broad range of biological modalities. As a premier partner for biopharmaceutical innovation, Coriolis Pharma provides expertise in developing liquid and lyophilized drug products, optimizing stability for proteins, peptides, nucleic acids, vaccines, gene and cell therapy products, and virus(-like) particles up to biosafety level S2. Its interdisciplinary team, supported by an expert scientific advisory board, delivers cutting‑edge, tailor-made solutions designed to accelerate and de-risk drug development programs throughout the entire product lifecycle. Coriolis Pharma’s service portfolio includes comprehensive analytical method development, qualification, and validation, ensuring robust regulatory support for biopharmaceutical pipelines. Its commitment to scientific excellence, innovation, and independent operation makes the company a trusted partner for biotechnology firms and pharmaceutical developers worldwide. Meet Coriolis Pharma at the BIO Convention to learn how their integrated development, analytical, and manufacturing services can help advance your biotherapeutic programs faster, safer, and more efficiently.
Cfm Oskar Tropitzsch GmbH
Cfm Oskar Tropitzsch GmbH assists the chemical, pharmaceutical and biotechnological industry in sourcing and producing chemical specialties. The core of our work is to supply the product which our customer is looking for – with the right documentation, the correct quantity from mg to mt and proper quality and this not only for a one shot business but to support projects from RnD state up to commercial production. To achieve these challenging goals Cfm Oskar Tropitzsch GmbH uses its excellent knowhow and worldwide network of qualified suppliers. Finding the best solution! …it’s not just a sentence – it’s our mission! | Cfm Oskar Tropitzsch GmbH assists the chemical, pharmaceutical and biotechnological industry in sourcing and producing chemical specialties. The core of our work is to supply the product which our customer is looking for – with the right documentation, the correct quantity from mg to mt and proper quality and this not only for a one shot business but to support projects from RnD state up to commercial production. To achieve these challenging goals Cfm Oskar Tropitzsch GmbH uses its excellent knowhow and worldwide network of qualified suppliers. Finding the best solution! …it’s not just a sentence – it’s our mission! Our product categories are: -ADC-Payloads -API`s -Contract Manufacturing / Contract Fermentation within Europe/US -Diagnostic Reagents like e.g. DTT -Excipients – Contract Manufacturing of Excipients (g-kg) -Metals & Metal Compounds -Peptide Synthesis -Pytochemicals -Small Molecules (Fermentation Products)
Celltrion, Inc.
A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business. | Celltrion is a leading global biopharmaceutical company dedicated to improving the health and well-being of patients. We have presented a new paradigm to the global biologics market with the launch of the world’s first monoclonal antibody biosimilar. Celltrion will continue to pursue its goal in promoting the health and well-being of patients.
Cellipont Bioservices
Cellipont Bioservices is a cell therapy CDMO with experience in the development and manufacturing of cell therapies. Our leaders have played an instrumental role in shaping the cell therapy development and manufacturing methods and technologies. Our technically strong team has been recognized by our partners for their ability to manufacture and release products successfully. Cellipont is committed in helping our partners to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities. Cellipont Bioservices has a team of subject-matter-experts with extensive experience in the translation of your process from benchtop to bedside. Our team has hands on experience within autologous and allogenic cell therapies, and native & genetically modified cells. We have proven in-house scientific and manufacturing expertise for all phases of clinical products for our range of clients from Pre-Clinical to Late Phase commercialization. Our extensive experience spans across multiple product areas, including: CAR-T/TCR-T DCs Fibroblasts NK MSCs HSCs TIL Cell Banking (MCB, WCB) Feeder Cell Banks Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 1,800 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont Bioservices’ growth with deep knowledge of what it takes to succeed in this space. Cellipont cell therapy scientists in lab Located in The Woodlands, Texas right outside of Houston, Cellipont Bioservices facilities and quality systems are GMP-compliant. Cellipont Bioservices is privately held. Our core investor, Great Point Partners, is a dedicated healthcare-focused investment firm with an extensive track record in successfully building biologics services businesses. | Cellipont Bioservices firmly believes that cell therapies deserve personalized and dedicated support. Our team is comprised of tenured experts within the cell therapy space, working on advancing a wide spectrum of cell modalities from CAR-T, iPSC to DCs and MSCs. Located in The Woodlands, Texas, we are strategically located near some of the best medical centers in the world. We strive to lead alongside our partners from the forefront of innovation, translating cutting-edge processes from lab to bedside. | Cellipont Bioservices is a contract development and manufacturing organization (CDMO) dedicated exclusively to advanced therapies, supporting biotech and biopharma companies developing cell therapies from preclinical stages through commercial supply. The company provides integrated development, analytical, and GMP manufacturing solutions designed to accelerate clinical timelines while maintaining regulatory readiness and product quality. The organization has commercial manufacturing experience, and its facility is designed to support both early clinical development and commercial programs. The organization specializes in autologous and allogeneic cell therapy modalities, including CAR-T, TCR-T, NK, stem cell, and other engineered immune cell products. Its services are structured to bridge the gap between early process concepts and scalable, regulatory-compliant manufacturing workflows, enabling sponsors to transition efficiently from research into clinical production and long-term commercial supply.
CatSci
Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, pre-formulation, analytical development, HPAPI development and non-GMP material supply, and recently launched their oligonucleotides capability. Through their partnership with AGC Pharma Chemicals, they offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. CatSci’s overall mission is to enable customers to create innovative therapeutics that will improve patient quality of life. They aim to become a ‘digital first, intelligent automation next’ business, freeing up the hands and minds of scientists through digital tools, enabling them to create perfect-for-purpose solutions that solve customers’ problems. Their purpose is and always will be to get medicines into the hands of patients in need. | CatSci Ltd is a UK-based award-winning innovation partner, dedicated to breaking down the silos in the development of small molecules, TACs and glues, and oligonucleotides to accelerate the delivery of life-changing medicines to patients in need. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule GMP API material supply, from grams to tonnes, with seamless knowledge transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the highly esteemed Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees) and STEM Ambassador of the Year), and the 2022 Cardiff Business Award (International Business of the Year). | CatSci Ltd is an award-winning innovation partner, dedicated to breaking down the silos in the CMC development of small molecules, TACS, glues, oligonucleotides and other complex medicines to accelerate the delivery of life-changing therapeutics to patients. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2024 Finance Awards Wales (ESG Excellence), the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees), and the 2022 Cardiff Business Award (International Business of the Year). | Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, preformulation, analytical development, HPAPI development and oligonucleotide development, they recently launched their peptide and bioscience capability.
C Ray Therapeutics (Chengdu) Co., Ltd.
C Ray Therapeutics Group operates an R&D center in Shanghai, focused on proprietary pipeline development. This covers early discovery, process development, clinical research, and registration. The company has established over 10 development pipelines targeting solid tumors, utilizing isotopes such as Cu-64, Lu-177, and Ac-225, with a variety of ligands, including small molecules, peptides, and modified antibodies. Several pipelines feature globally innovative molecules with independent intellectual property rights. | C-Ray Therapeutics is dedicated to delivering end-to-end solutions for innovative radiopharmaceuticals to clients around the world. Our services span process development, quality research, preclinical evaluation, IND Enabling, clinical supply, and commercial scale cGMP production, all backed by a reliable, robust logistics network. As of 2024, we have raised over USD 187 million in total funding. C-Ray has 28,000 square-meter, state-of-the-art, world class R&D and cGMP manufacturing facilities with the highest Class A Radiation Safety License, allowing commercial scale operational volume of over 30+ radioisotopes. GLP-like preclinical study center has both small and large lab animal use permit with animal feeding and administration lab, animal PET/CT for imaging, gama counter and pathology lab for biodistribution and dosimetry analysis. C-Ray has successfully delivered and continues to operate 70 CRDMO projects, including 50 preclinical and molecular imaging CRO projects and 24 CDMO projects. Among these, 5 have entered the IND and IND-enabling stages, 16 have advanced to investigator-initiated trials (IITs), and 5 have entered the clinical supply stage, with 2 of them successfully progressing to a Phase III clinical study. The company has achieved comprehensive coverage of all critical links across the entire radiopharmaceutical R&D and manufacturing chain. As a dedicated CRDMO partner in radiopharmaceuticals, one of our core strengths is a stable, diversified supply of radionuclides. We are actively developing high-quality domestic sources while playing a leading role in integrating and fortifying the global supply chain—most notably securing access to challenging isotopes such as Ac-225. To date, we have supported the development of 19 Ac-225–labeled projects.
BSP PHARMACEUTICALS S.p.A
BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a specific focus on innovative compounds. With full containment facility, applying the most advanced and safe technologies, BSP can offer capabilities with a wide range of batch sizes providing flexibility to sustain preclinical, clinical and commercial manufacturing. The facility is designed to handle small molecules and large molecules, including ADCs (from Conjugation to Fill Finish), mAbs (including bi-specific), synthetic peptides, oligonucleotides, lipidic nanomedicine Production area includes: – a plant dedicated to Cytotoxic compounds, small and large molecules, (OEL
Bionova Scientific
Based in Fremont, California, Bionova Scientific is a rapidly growing biologics CDMO offering world-class services built on a foundation of strong process development and analytical science. Our team shares decades of experience in late stage and commercial launch projects, specializing in mammalian cell culture production of mAbs, bispecifics, fusion proteins and other recombinant proteins. We operate a brand-new commercial-ready GMP biologics manufacturing facility to provide clinical and commercial production for clients and recently initiated an expansion program that will quadruple our GMP manufacturing capacity. We are currently booking slots for 2023 and beyond. Our upstream PD group, with more than 60 benchtop bioreactors, offers capabilities typically found in CDMOs five times our size. | Bionova Scientific is an Asahi Kasei company based in Fremont, California. Bionova Scientific is a full-service biologics CDMO offering world-class services built on a foundation of strong process development, cell line development and analytical science. Our team shares decades of experience in late stage and commercial launch projects, specializing in mammalian cell culture production of mAbs, bispecifics, fusion proteins and other recombinant proteins. We operate a brand-new commercial-ready GMP biologics manufacturing facility to provide clinical and commercial production for clients and recently initiated an expansion program that will quadruple our GMP manufacturing capacity. Our upstream PD group, with more than 60 benchtop bioreactors, as well as the ambr15 and ambr250 platforms offering capabilities typically found in CDMOs five times our size. | Bionova Scientific is a flexible, fast-moving CDMO focused on recombinant protein therapeutics and plasmid DNA. With a strong foundation in cell line development, process development and analytical sciences, we operate a brand-new commercial-ready GMP biologics manufacturing facility to provide clinical and commercial production for clients (with additional expansion underway). Our team shares decades of experience in late stage and commercial launch projects, specializing in mammalian cell culture production of complex recombinant proteins, including mAbs, multispecifics, and fusion proteins. Bionova Scientific is an Asahi Kasei company. | Bionova Scientific is a bespoke CDMO providing end-to-end development and GMP manufacturing services for recombinant proteins and plasmid DNA. We support biotherapeutic programs at any stage, from cell line development through commercial-ready manufacturing. Protein operations are based in Fremont, California, with a dedicated plasmid DNA facility in Houston, Texas offering plasmid design through GMP production. Founded in 2014 and acquired by Asahi Kasei in 2022, Bionova combines CDMO agility with the global resources and financial strength of a leading bioprocessing organization.